Research Summary

Bruno Lab uses synthetic biology and high-throughput functional genetic screens to expand our ability to interrogate and manipulate the immune system. Our new tools for understanding antigen presentation and T-cell recognition are being applied to cancer and other diseases with the goal of developing new immunotherapies and better implementing existing ones. 

Education

Ph.D., 06/2016 - Biology, Massachusetts Institute of Technology
B.S., 06/2010 - Molecular Biology, University of California, San Diego

Honors & Awards

  • 2022
    Award for Best Poster, New England Immunology Conference
  • 2018-2020
    HHMI Jane Coffin Childs Memorial Fellow
  • 2015
    Kock Institute Marlena Felter Bradford Research Travel Fellowship

Selected Publications

  1. Bruno PM, Timms RT, Abdelfattah NS, Leng Y, Lelis FJN, Wesemann DR, Yu XG, Elledge SJ. High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform. Nat Biotechnol. 2023 Jul; 41(7):980-992.  View on PubMed
  2. Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2020 Apr 17; 11(1):1940.  View on PubMed
  3. Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, Elledge SJ, Hemann MT, Pritchard JR. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc Natl Acad Sci U S A. 2020 02 25; 117(8):4053-4060.  View on PubMed
  4. Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2018 02 07; 9(1):628.  View on PubMed
  5. Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2017 12 18; 8(1):2166.  View on PubMed
  6. Tang YC, Yuwen H, Wang K, Bruno PM, Bullock K, Deik A, Santaguida S, Trakala M, Pfau SJ, Zhong N, Huang T, Wang L, Clish CB, Hemann MT, Amon A. Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis. Cancer Res. 2017 10 01; 77(19):5272-5286.  View on PubMed
  7. Flamme M, Cressey PB, Lu C, Bruno PM, Eskandari A, Hemann MT, Hogarth G, Suntharalingam K. Induction of Necroptosis in Cancer Stem Cells using a Nickel(II)-Dithiocarbamate Phenanthroline Complex. Chemistry. 2017 Jul 18; 23(40):9674-9682.  View on PubMed
  8. Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017 Apr; 23(4):461-471.  View on PubMed
  9. Eskandari A, Boodram JN, Cressey PB, Lu C, Bruno PM, Hemann MT, Suntharalingam K. The breast cancer stem cell potency of copper(ii) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles. Dalton Trans. 2016 Nov 28; 45(44):17867-17873.  View on PubMed
  10. Barnes JC, Bruno PM, Nguyen HV, Liao L, Liu J, Hemann MT, Johnson JA. Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity. J Am Chem Soc. 2016 09 28; 138(38):12494-501.  View on PubMed
  11. Cressey PB, Eskandari A, Bruno PM, Lu C, Hemann MT, Suntharalingam K. The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-Cyclam Complex on Cancer Stem Cells. Chembiochem. 2016 09 15; 17(18):1713-8.  View on PubMed
  12. Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT. Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. Proc Natl Acad Sci U S A. 2016 07 05; 113(27):E3892-900.  View on PubMed
  13. Zheng YR, Suntharalingam K, Bruno PM, Lin W, Wang W, Hemann MT, Lippard SJ. Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage. Inorganica Chim Acta. 2016 Oct 01; 452:125-129.  View on PubMed
  14. Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ. Correction to "A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy". J Am Chem Soc. 2016 Mar 09; 138(9):3250.  View on PubMed
  15. Boodram JN, Mcgregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K. Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes. Angew Chem Int Ed Engl. 2016 Feb 18; 55(8):2845-50.  View on PubMed
  16. Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. J Am Chem Soc. 2015 Dec 02; 137(47):14854-7.  View on PubMed
  17. Suntharalingam K, Awuah SG, Bruno PM, Johnstone TC, Wang F, Lin W, Zheng YR, Page JE, Hemann MT, Lippard SJ. Necroptosis-inducing rhenium(V) oxo complexes. J Am Chem Soc. 2015 Mar 04; 137(8):2967-74.  View on PubMed
  18. Suntharalingam K, Lin W, Johnstone TC, Bruno PM, Zheng YR, Hemann MT, Lippard SJ. A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex. J Am Chem Soc. 2014 Oct 15; 136(41):14413-6.  View on PubMed
  19. Suntharalingam K, Johnstone TC, Bruno PM, Lin W, Hemann MT, Lippard SJ. Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. J Am Chem Soc. 2013 Sep 25; 135(38):14060-3.  View on PubMed
  20. Pritchard JR, Bruno PM, Hemann MT, Lauffenburger DA. Predicting cancer drug mechanisms of action using molecular network signatures. Mol Biosyst. 2013 Jul; 9(7):1604-19.  View on PubMed

Go to UCSF Profiles, powered by CTSI